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1. Introduction 
Autism spectrum disorders (ASD) are part of a broad spectrum of neurodevelopmental 
heterogeneous disorders known as pervasive developmental disorders (PDD), which 
include autism, Asperger’s syndrome, Rett’s disorder, and childhood disintegrative 
disintegrative disorder. By description, ASD are characterized by impairments in verbal and 
nonverbal communication and social interaction (Association, A. P., 1994), with onset 
usually around the first 36 months of childhood. Repetitive, stereotyped, purposeless 
behaviors as well as attention and sensory dysfunctions are common findings in patients 
with ASD. Over the last few years, the prevalence of ASD has increased dramatically, and 
this increase, cannot be attributed entirely to improved diagnostic techniques and increased 
awareness only (Fombonne, 2003). Latest reports estimate that ASD affects approximately 
one per one hundred persons, with a male-to-female ratio of four to one (4:1) (Fombonne, 
2003). Despite that the fact there is increase in ASD research worldwide, the exact etiology of 
autism and ASD remains largely unknown. Over the last few years, a scientific interest has 
occurred in the close relationship of the immune system to the central nervous system 
leading to considerable expansion in the field of psychoneuroimmunology. And currently it 
is widely accepted that environmental factors can compromise the immune system. A multi 
directional scientific approach has been adopted by many scientists in their research journey 
as it is likely to result from a complex combination of environmental, neurological, 
immunological, and genetic factors. There is emerging evidence and growing concern that a 
dysregulated or abnormal immune responses play an important role in some forms of ASD. 
In general, the associations between the immune and neurological systems are becoming 
more evident in many neurological disorders. Behaviors such as mood and sleep can be 
altered by cytokines and other products of immune activation, due to widespread effects on 
neurons. Aberrant immune activity during the early critical periods of brain and neuronal 
development could potentially play a role in neuronal dysfunction. Several efforts have 
attempted to link dysfunctional immune activity and ASD, such as maternal immune 
abnormalities during early pregnancy, increased incidence of familial autoimmunity, and 
childhood vaccinations. Several lines of research have shown abnormalities of the immune 
response in autism, including abnormal generation of antibodies, cytokines, and immune 
cells. The following chapter is a review of current research linking immune dysfunction to 
ASD. 
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2. Neurological abnormalities in autism spectrum disorders  
Neural development takes place during the early years of life. During this period of time, 
neuronal differentiation, migration, axonal extension, and synapse formation takes place in 
an accurately designed sequence of events. In ASD, many neurological abnormalities have 
been found, which suggest that normal neurodevelopment was disturbed during a critical 
time of development, which include proliferation, migration, differentiation, 
synaptogenesis, gliogenesis, myelination, and apoptosis of neurons (Rice & Barone Jr., 2000). 
This critical time period extend from embryonic stage up until adolescence, with period of 
overlap at some stages. Quarter of autistic patients undergo a period of autistic regression, 
around 18th–24th months of age, during which they experience loss of previously acquired 
language and behavioral skills (Fombonne, 2003). Postmortem and neuroimaging magnetic 
resonance imaging (MRI) studies played an important role in the discovery of many 
neurological abnormalities in autistic patient’s brains. These studies have suggested that 
many major brain structures may be affected in autism, including cerebellum, cerebral 
cortex, amygdala, hippocampus, corpus collosum, basal ganglia, and brain stem 
(Akshoomoff et al.,2002; Acosta et al., 2004; Courchesne et al., 2001). These abnormalities 
suggest multiple periods of prenatal onset. Furthermore, brain regions implicated in ASD 
tend to develop more slowly and are more vulnerable to disturbances. Cerebellar 
abnormalities have been observed as the most consistent finding in ASD, targeting in 
particular Purkinje and granular cells (Courchesne, 2002). Another important area which 
was found to be abnormal in ASD is the limbic system. The limbic system, whose 
components include the amygdala, hippocampus, cingulate gyrus, and septal nuclei, 
consists of a group of nuclei unified by a common function. The limbic system controls 
emotional behavior and any changes in body state that accompany this behavior, such as 
heart rate blood pressure, and respiration rate. Due to its role in emotion, the limbic system 
is of major interest in ASD patients; so far, the abnormal findings include increased cell 
packing and small neuronal size, indicative of cellular, maturational arrest (Akshoomoff et 
al., 2002; Palmen et al., 2004). Other neurological abnormalities described in ASD are 
abnormal EEG findings: around third of children with ASD develop epilepsy by adolescence 
(Volkmar et al., 1999), and an additional, significant minority has subclinical epilepsy, as 
measured by epileptiform encephalogram, especially during sleep (Tuchman et al., 1991). 
These findings clearly indicate that there are neurological involvements in ASD that affect 
the development and differentiation of neurons in the brain.  
2.1 Structural magnetic resonance imaging findings  
Structural magnetic resonance imaging (SMRI) studies played a major role in highlighting 
brain changes in ASD.  SMRI confirmed the increase in total brain volume in autism, which 
present as increase in head circumference, starting around 2 to 4 years of age (Hazlett et al., 
2005, Courchesne et al., 2001). This increase was attributed mainly to increase in total 
cerebral white matter and total cortical gray matter. The inner zone of white matter, 
especially the corpus callosum and internal capsule, showed no volume increase. The 
volume of the outer radiate white matter was increased in all cerebral lobes but with a 
frontal predominance. Collectively, these findings were interpreted as evidence of 
overgrowth of short- and medium-range intrahemispheric corticocortical connections with 
no detectable involvement of interhemispheric connections or connections between cortex 
and subcortical structures. The onset of brain overgrowth coincided with the onset of the 
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signs and symptoms of autism, signifying that the overgrowth was part of a pathologic 
process that disrupted the development of normal brain structure and function in autism.  A 
recent study, by Jieun et. al., (2010), recruiting a narrow age range of children with ASD and 
age-matched typically developing (TD) children, evaluating alterations in subregional 
amygdalar morphology. The group showed a bilateral enlargement of laterobasal subregions 
of the amygdala in 6- to 7-year-old children with ASD and that subregional alterations are 
associated with deficits in social and communicative behavior (Jieun et al., 2010)  
2.2 Functional magnetic resonance imaging studies findings  
Further understanding of autism was made from functional magnetic resonance imaging 
(fMRI) studies. During cognitive processing, subjects with autism use the same cortical 
areas, compared to aged matched control. Important remarkable variations have been found 
in the patterns of activation and in the timing or synchronization of the activation across the 
cortical network recruited to perform different tasks. fMRI study of written sentence 
comprehension has indicated that high-functioning adults with autism has relatively higher 
levels of activation in the left posterior superior temporal gyrus (Wernicke) and relatively 
lower levels of activation in the left frontal inferior gyrus (Broca) compared with age- and 
IQ-matched controls (Just et al., 2004). In addition, a reduction in functional connectivity,  
that is the correlation of the time series of the activation among cortical regions participating 
in performance of higher order tasks, was noted. Lower functional connectivity relative to 
the control group among participating cortical regions has been found in fMRI studies 
involving language (Just et al., 2004; Kana et al., 2006) working memory (Koshino et al., 
2005), problem solving (Cherkassky et al., 2007), and social cognition (Castelli et al., 2002) 
providing further evidence of a general problem with functional under connectivity, within 
and between neocortical systems in autism. Functional imaging findings in autism have 
been consistent with a cognitive style favoring the use of visuospatial coding strategies, 
evident in increased reliance on extra striate and parietal regions (Manjaly et al., 2007). This 
could reflect a disruption in fronto-striatal and fronto-parietal functional connectivity (Just 
et al., 2007), abnormal activation within frontal and temporal regions has been related to the 
linguistic difficulties in this population (Groen et al., 2008). 
2.3 Cortical connectivity in autism spectrum disorders 
Cortical connectivity was examined in autism spectrum disorders by comparing gyral and 
sulcal thickness as indices of short- and longer-distance cortical connections (Hardan  et al., 
2006). The results showed an overall increase in cortical thickness in 8 to 12year old boys 
with autism compared to control. Furthermore, the study demonstrated that cortical 
thickness in sulci (long connections) was greater (analogous to increased volume of outer 
radiate white matter) than in gyri (short vertical connections), which is comparable to the 
findings of Herbert and colleagues for white matter (Herbert et al., 2004). Another 
significant finding was abnormalities in minicolumns structure in brain of autistic children. 
Minicolumns are composed of radically oriented arrays of pyramidal neurons (layers II-VI), 
interneuron’s (layers I-VI), axons, and dendrites. Minicolumns assemble into macrocolumns, 
which form receptive fields. Minicolumns have been hypothesized to be the smallest radial 
unit of information processing in the cortex, but this function has not been confirmed. In 
autism spectrum disorders, reports indicate an increase in miniclomns number but narrower 
in width, with reduced neuronal space, with smaller neuron cell bodies and nucleoli 
www.intechopen.com
 
Autism – A Neurodevelopmental Journey from Genes to Behaviour 302 
(Casanova et al., 2006). These abnormalities have been observed bilaterally in cortical areas 3, 
4, 9, 17, 21, and 22. The description of these cortical abnormalities provides a critical 
counterbalance to the numerous reports of increased white matter volume, which might 
otherwise have led to a white matter model of autism. Findings of atypical patterns in both 
functional and anatomical connectivity in autism have established that autism is a not a 
localized neurological disorder, but affects many parts of the brain in many types of cognitive 
tasks. fMRI studies repeatedly find evidence of decreased coordination between frontal and 
posterior brain regions in autism, as measured by functional connectivity. In addition, 
neuroimaging studies have also revealed evidence of an atypical pattern of frontal white 
matter development in autism. These findings indicate that limitations of brain connectivity 
give rise to the varied behavioral deficits found in autism. As research continues to investigate 
these biological mechanisms, new intervention methods may develop to help improve brain 
connectivity and overcome the behavioral impairments of autism. 
3. Autoimmunity in autism spectrum disorders  
3.1 General immunological findings in autism spectrum disorders  
Autoimmunity develops when the immune system is inappropriately directed to recognize 
and exert an exaggerated response to self components. The exact mechanism of 
autoimmunity in autoimmune diseases is not identical, but they all have autoreactive 
antibodies and T cells. The presence of antibodies directed against components of the CNS 
in the sera of autistic children is indicative of an autoimmune process that may be involved 
in the pathology of some cases of ASD. Almost with all autoimmune diseases, genetic, 
immune and environmental factors, such as, diet, toxic chemicals and infections, play critical 
roles in the development of the disease (Buehler, 2011; Vojdani et al., 2002; Kiberstis et al., 
2002). Casein, casomorphins, gluten (GLU) and gluteomorphins, the opioid peptides, which 
is present in a range of food sources, are all implicated in the etiology of autism spectrum 
disorders. These peptides can stimulate T-cells, induce peptide specific T cell responses, and 
can lead to abnormal levels of cytokine production, which may result in inflammation, 
autoimmune reactions and disruption of neuroimmune communications (Jyonouchi et al., 
2001). In autism spectrum disorders majority of children have wheat and milk protein 
intolerance. And accordingly, removal of these peptides from the diets significantly 
improves their conditions (Vojdani et al., 2002). Immunoglobulines, such as, IgG, IgM and 
IgA, were detected, against nine specific neuron-specific antigens in the sera of children 
with autism (Vojdani et al., 2002). These antibodies were found to bind with different central 
nervous system molecules that have sequence homologies to a milk protein. 
Long exposure to toxic, environmental or occupational chemicals, have been shown to 
stimulate the production of autoantibodies to nervous system antigens. Titers of antibodies 
against neurofilaments and myelin basic protein (MBP) correlated significantly with urinary 
mercury and blood lead levels, the standard indicators of toxic exposure. In addition, levels 
of these antibodies proved to correlate with sensorimotor deficits. Gut-associated lymphoid 
tissues (GALT) can interact with toxins, chemicals and pollutants. If covalent reactions are 
formed between the drugs or other chemical compounds and the GALT, this can lead to 
immune responses and chemically-induced Type I- Type IV allergic reactions (Salama et al., 
1989). Many infectious agents including measles, Rubella virus and Cytomegalovirus 
vaccines have long been suggested as etiologic factors in autism (Chess et al., 1978.; 
Wakefield et al., 1998; Ivarsson et al., 1990).  
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A complex communication system does exist between the nervous and the immune system, 
during normal and pathological conditions. Alteration in brain function can result from 
immune cells and molecules, such as cytokines and chemokines. This might affect cognition 
and emotions. Furthermore, immune cells and immune molecules can result in neuronal 
modulation of systemic CNS responses to infection, injury, and inflammation. The cytokines 
have been shown to directly affect neural tissue function and development, especially the 
proinflammatory cytokines such as interleukin (IL)-1, IL-6, IL-12, interferon-(IFN), and 
tumor necrosis factor (TNF) (Jarskog et al., 1997; AL-Ayadhi, 2005a). Inflammatory cytokine 
IL-6 can induce sleep, and TNF can provoke anorexia (Steinman et al., 2003; Tracey et al., 
1988). Cytokines have been suggested to be responsible for  many common features of 
autism, such as mood and sleep disturbances. In turn, neuropeptides, derived from the 
central and peripheral nervous system, have profound effects on the immune system, 
including the chemotaxis and recruitment of innate immune cells (Tracey et al., 1988). A 
dysregulated immune function has been suggested by many scientists. Systemic, 
immunologic abnormalities in autism have been related to autoimmunity, leading to the 
generation of antibodies that are reactive to CNS proteins and have the potential for 
neuronal tissue destruction, or leading to an inappropriate or ineffective immune response 
to pathogen assault (Korvatska et al., 2002). Several immune abnormalities, suggestive of, 
dysregulated immune response reported in autistic children include incomplete or partial T 
cell activation evidenced by increased numbers of T cells without the expression of the -2 
receptor (IL-2R) (Warren et al., 1986; Plioplys et al., 1994), dysregulated apoptosis 
mechanisms (Korvatska et al., 2002), decreased peripheral lymphocyte numbers [30], 
decreased response to T cell mitogens (Warren et al., 1986; Stubbs et al., 1977) and the 
imbalance of serum Ig levels [30, 57]. Furthermore, immune-based genes including class II 
HLA-DRB1 alleles, class III complement C4 alleles, and HLA-extended haplotypes have 
been linked to autism spectrum disorders (Odell et al., 2005; Torres et al., 2001).  
Animal models have also contributed to strengthening the dysregulated immune system 
hypothesis in the etiology of autism spectrum disorders which indicate that the maternal 
immune response to infection can influence fetal brain development via increased levels of 
circulating cytokines (Yamashita et al., 2003; Patterson et al., 2002). Mouse models of 
maternal influenza virus infection at mid-gestation have similar neuropathological and 
behavioral abnormalities in the offspring, which are consistent with those seen in autism 
and were again suggestive of a strong immune component (Patterson, 2002; Shi et al., 2003). 
Furthermore, infection of neonatal rats with Borna disease virus (BDV) leads to neuronal 
death in the hippocampus, cerebellum, and neocortex and a behavioral syndrome that has 
similarities to autism (Hornig, 2002). These abnormalities are correlated with major 
alterations of cytokine expression in various brain regions, indicating a likely role of 
cytokines as mediators of CNS injury in this model (Buehler, 2011; Plata-Salaman et al., 1999; 
Sauder & de la Torre, 1999).  
Autoimmunity was first linked to autism in a study of an autistic child, with strong family 
history of autoimmune diseases (Money et al., 1971). This study suggested that an inherited 
risk of autoimmunity could increase the risk of developing autism. Another study, 
investigated the frequency of autoimmune disorders in family members of 61 ASD children 
and 46 typically developing normal controls, and showed the mean number of autoimmune 
disorders to be greater in families with autism (Comi et al., 1999). In most of these cases, the 
individual with the autoimmune disorder was a first-degree relative (i.e., a sibling or a parent) 
of the autism child (Comi et al., 1999). A variety of anti-brain antibodies have been found in 
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autistic patients, including autoantibodies to serotonin receptor , myelin basic protein (MBP), 
neuron axon filament protein, cerebellar neurofilaments, nerve growth factor, 2-adrenergic, 
adrenergicbinding sites, anti-brain endothelial cell proteins, and antibodies directed against an 
as-yet unknown brain protein (Rosse et al., 2011; Buehler, 2011; AL-Ayadhi, 2005b; Singh et al., 
1993;  Singh et al., 1997; Todd et al., 1988; Connolly et al., 1999;  Silva et al., 2004; Todd & 
Ciaranello, 1985). However it is still unclear as to the pathophysiological significance of these 
antibodies reported in children with ASD. For instance, increased autoantibodies is suggestive 
of increased neuronal damage, as is the case in multiple sclerosis, and other autoimmune 
diseases, where following demyelination, MBP is unmasked, and there is a subsequent 
generation of antibodies. Nevertheless, evidence of demyelination in autism has remained 
indefinable (Rumsey & Ernst, 2000). In one study, Glial fibrillary acidic protein (GFAP) 
measured in the CSF of 47 ASD children, was significantly elevated compared with 10 age-
matched control children, suggesting that gliosis and unspecific brain damage may occur in 
autism (Ahlsen, et al., 1993). However, as GFAP correlates strongly with age, this is likely to be 
the result of age-dependent expansion of fibrillary astrocytes, and hence the data needs to be 
interpreted cautiously (Delneste, et al., 1999). Nevertheless, the importance of the presence of 
serum antibodies to brain tissues, regardless of the absence of neuronal damage is to be 
acknowledged. Singh and Rivas (2004), demonstrated antibodies directed to the rat caudate 
nucleus (the portion of the brain responsible for assembly of peripheral information) in 49% of 
the autism patients evaluated, but in none of the control cases. The observations of elevated 
anti-CNS antibodies in autism are at best unconfirmed and in some cases, such as serotonin 
receptors and MBP, are contradictory. It is important to keep in mind the difficulty in 
determining whether the autoantibodies present in the plasma of patients with autism 
contribute to the development of the disorder or if they are a consequence of the disease. Also, 
findings of autoimmunity in families of children with ASD suggest that in some patients, 
autoantibodies that target the CNS may be a pathological or an exacerbating factor in the 
neuronal development of children with ASD. However, increased autoimmunity may be 
limited to a subset of autistic patients (Buehler, 2011; Singh & Rivas, 2004). An important 
finding was reached by Wills research group (2009), they demonstrated that 21% the positive 
autoantibodies samples, reacted intensely with GABAergic Golgi neurons of the cerebellum 
while no samples from non-sibling, typically developing children showed similar staining 
(Wills et al., 2009). Further more, Rossi et al., (2011), demonstrated that 42% of controls and 
subjects with ASD were positively immunoreactive to some neural element, such as, cerebellar 
Golgi, interneurons, molecular layer of the dentate gyrus, and neuronal nuclei. Interestingly, 
children whose plasma reacted to brain tissue had scores on the Child Behavior Checklist 
(CBCL) that indicated increased behavioral and emotional problems. Children whose plasma 
was immunoreactive with neuronal cell bodies scored higher on multiple CBCL scales (Rossi 
et. a., 2011). 
It is quite interesting to mention the results of a large cohort study consisted of all of the 
children born in Denmark from 1993 through 2004 (689 196 children). The study concluded 
the following: associations between family history of type 1 diabetes, infantile autism and 
maternal history of rheumatoid arthritis and ASDs were confirmed from previous studies. A 
significant association between maternal history of celiac disease and ASDs was observed 
for the first time. The observed associations between familial autoimmunity and 
ASDs/infantile autism are probably attributable to a combination of a common genetic 
background and a possible prenatal antibody exposure or alteration in fetal environment 
during pregnancy (Nancy et al., 2011). 
www.intechopen.com
 
Autoimmunity in Autism Spectrum Disorders 305 
3.2 Maternal immune system status findings  
Maternal immune abnormalities such as autoimmune diseases, asthma, and allergies during 
pregnancy were investigated for a link to autism by Croen and colleagues (Croen,  et al., 
2005). They found no strong evidence linking maternal autoimmune diseases and autism. 
However, it was found that mothers diagnosed with asthma or allergies during their second 
trimester were more than twice as likely to have a child with autism (Croen, et al., 2005). To 
date, no studies have demonstrated that ASD children have an increased frequency of other 
autoimmune disease, the exception being whether ASD itself could be considered an 
autoimmune disease. Furthermore, due to the fact that the manifestation of autoimmune 
disease occur around the age of 30 and upward, and as the ASD cases studied are pediatric 
cases, it is worth following up the ASD cases to determine whether more autoimmune 
diseases will be observed as they mature. Serum from a mother with an autistic child was 
found to bind to Purkinje cells and other neurons, when injected into gestating mice. 
Furthermore, a behavioral change in mice was observed in the offspring, including altered 
exploration, motor coordination, and changes in cerebrallar magnetic resonance 
spectroscopy. On the other hand, mice injected with sera from mothers with typically 
developing children showed no behavioral changes (Dalton et al., 2003). This study supports 
the suggestion that maternal antibodies may influence neurodevelopmental processes in a 
subset of autism cases.  
Interlukin 1 (IL-1) plays a key role in mediating severe placental damage and 
neurodevelopmental anomalies in offspring, as revealed by Girard et al. (2010). This group 
demonstrated that at the end of gestation, exposure of pregnant rats to systemic microbial 
product (LPS) triggers placental inflammation and massive cell death, fetal mortality, and 
both forebrain white matter and motor behavioral alterations in the offspring. All these 
effects are alleviated by the coadministration of IL-1 receptor antagonist, suggesting a 
possible protective treatment against human placental and fetal brain damage (Gerard et al., 
2010) 
3.3 Cytokines role in autism spectrum disorders 
Cytokines (Chemokines) are a family of small proteins secreted by immune cells. They have 
the ability to induce directed chemotaxis in nearby responsive cells. Some chemokines are 
considered pro-inflammatory and can be induced during an immune response to recruit 
cells of the immune system to a site of infection. These proteins exert their biological effects 
by interacting with G protein-linked transmembrane receptors called chemokine receptors 
found on the surfaces of their target cell. Several studies have demonstrated elevated plasma 
levels of IL-12 and IFN- in autistic children compared with controls, with no changes for IL-
6, TNF- and IFN- (Singh, 1996) plasma levels, suggesting a potential TH1 shift. On the other 
hand, another study demonstrated, higher plasma IFN- in 10 autistic children compared 
with adult control subjects (Jyonouchi et al., 2005). Moreover, an increased plasma IFN- 
levels were observed in 29 autistic children; with a positive correlation with the generation 
of the intercellular CNS messenger and marker of oxidative stress, nitric oxide (NO) 
(Sweeten et al., 2004). The same research group observed that the macrophage product 
neopterin, was higher in serum samples from individuals with ASD compared with 
controls, which may reflect increased cell-mediated immune activation and IFN- production 
(Sweeten et al., 2003). Higher IFN- and neopterin levels correlated significantly with 
elevated, circulating numbers of monocytes observed in autistic children (Sweeten et al., 
2003) with elevated urine levels of neopterin and biopterin (Messahel et al., 1998).  
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In cell culture experiments, in which intracellular cytokine production was examined in 20 
autistic patients, compared with 20 aged-matched controls, intracellular production of IL-4 
was increased, with a reduction in IFN- and IL-2 in CD4 and CD8 lymphocytes following 
stimulation (Gupta et al., 1998), suggestive of a TH2 bias. In vitro studies of peripheral blood 
mononuclear cells stimulated with lipopolysaccharide (LPS), showed an inappropriate 
innate immune response evidenced by amplified production of proinflammatory cytokines 
TNF- and IL-1 in ASD patients compared with controls (Jyonouchi et al., 2001). This 
immune dysregulation of increased TNF- was also found in primary sibling family members 
of patients with ASD, indicating a possible similar genetic susceptibility in the patients 
studied. This emphasizes the importance of carefully controlled, age-matched studies in the 
field of ASD. Moreover, the diversity of the findings reinforces the idea that ASD consists of 
many different phenotypes, which share the same behavioral commonalities. Cytokines can 
activate and exert trophic effects on glial cells, which can in turn produce cytokines and 
chemokines upon such activation. Cell culture studies have shown that neuropoietic 
cytokines such as IL-6 can have direct effects on neurons and glia, including changes in 
proliferation, survival, death, neurite outgrowth, and gene expression (Gadient. & Patterson, 
1999; Mehler & Kessler, 1998). As the CNS is populated largely by astroglia and microglial 
cells, these cytokine-cell interactions are important for neuronal cell functioning and 
development. Immune activation in postmortem brain specimens and CSF from subjects 
with autism have found neuroinflammation in the cerebral cortex and cerebellum of brain 
tissue in autism was found. This inflammatory process was characterized by a marked 
cellular activation of microglial and astroglial cells and the presence of an altered cytokine 
pattern. In addition, there was an accumulation of perivascular macrophages and 
monocytes but an absence of lymphocytes and antibody from the brain specimens, 
suggestive of an innate immune activation. In addition, an enhanced proinflammatory 
cytokine profile was observed in their CSF. Abnormal immune responses in the neuroglia of 
autistic patients was suggested, which in turn may influence neural function and neural 
development, and an aberrant immune response may contribute to the development of 
autism. In general, the brain and CNS are considered to be protected and isolated from 
potentially harmful pathogens or agents within the blood, including inflammatory immune 
cells and proteins, by the blood brain barrier (BBB). Cytokines however, can gain entry into 
the brain through active transport mechanisms or at circumventricular regions, where the 
barrier is less controlling (Wilson et al., 2002). Impairment of the BBB function may happen 
as a result of binding of cytokines and inflammatory mediators to receptors on the 
endothelial cells directly. In addition, cytokines can migrate into the brain from the blood 
via the CSF to the choroid plexus or from the blood to either the subarachnoid space or 
parenchymalperivascular space, resulting in alteration in immune responses and production 
of cytokines (Ransohoff et al., 2003).  
Peripheral cytokines can directly affect afferent neurons and their functions (Dantzer et al., 
1998). Immune organs such as bone marrow, thymus, spleen, and lymph nodes play an 
important role in immune system development. Additionally, immune response is capable 
of changing expression and distribution of neural receptors in these organs (Mignini et al., 
2003). Thus the relationship is reciprocal between immune system and neural receptors. 
Cytokines can affect many behaviors such as, sleep, mood, appetite and nutritional uptake, 
exploratory behavior, and, social interactions and communication. Systemic cytokine 
administration at therapeutic doses of IFN-, IL-2, and TNF can result in mood changes, sleep 
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disorder, decreased exploratory behavior, impaired cognitive function, and changes in 
enthusiasm and motivation (Larson , 2002; Licinio et al., 1998). Systemic administration of 
cytokines can produce an increased noradrenergic, dopaminergic, and serotonergic 
metabolism in the hypothalamus, hippocampus, and nucleus accumbens and modulate 
synaptic plasticity and thereby alter memory and learning (Zhao, B., & Schwartz, J. P., 1998). 
Many studies have demonstrated abnormal levels of blood lymphocytes in autism. 
Significantly decreased CD4 T cells have been observed in ASD (Warren et al., 1990; Denney 
et al., 1996; Ferrante et al., 2003; Yonk et al., 1990). In animal models, systemic T cell 
deficiency in mice have been shown to result in learning and memory impairment, which is 
reversible by T cell replacement (Kipnis et al., 2004). Furthermore, an incomplete or partial 
activation of T cells following stimulation, with an increased expression of HLA-DR but not 
the IL 2R chain (CD25), was observed in ASD (Engstrom et al., 2003; Plioplys et al., 1994). 
NK cells are an important cytotoxic cell subset of the innate immune system and a major 
producer of cytokine. Reduced levels of circulating numbers of NK cells number and 
activity was observed in children with ASD and other related neurodevelopmental 
disorders, such as, Rett syndrome, compared with controls (Fiumara et al., 1999; Warren et 
al., 1987). In turn this reflects on its ability to eradicate or prevent viral infections in these 
children, which could potentially be damaging to neural tissues during critical windows of 
CNS development. Abnormal concentrations of plasma Ig classes have been observed in 
some ASD children with increased IgG2, IgG4, IgM and IgG (Ashwood et al., 2003; 
Croonenberghs et al., 2002; Trajkovski et al., 2004), highly indicative of an underlying 
autoimmune disorder and/or an atypical susceptibility to infections. 
Cytokines activity in the brain tissue of ASD and matching normal subject was examined by 
Xiaohong et al., (2009). Results showed that proinflammatory cytokines (TNF- α, IL-6 and 
GM-CSF), Th1 cytokine (IFN-γ) and chemokine (IL-8) were significantly increased in the 
brains of ASD patients compared with the controls. However the Th2 cytokines (IL-4, IL-5 
and IL-10) showed no significant difference. The Th1/Th2 ratio was also significantly 
increased in ASD patients. They concluded that ASD patients displayed an increased innate 
and adaptive immune response through the Th1 pathway, suggestive of a localized brain 
inflammation and autoimmune disorder involvement in the pathogenesis of ASD (Xiaohong 
et al., 2009). Flow cytometric analysis of NK cells demonstrated increased production of 
perforin, granzyme B, and interferon gamma (IFNγ) under resting conditions in children 
with ASD. Following NK cell stimulation in the presence of K562 target cells (cells used to 
assess NK cell cytotoxicity), the cytotoxicity of NK cells was significantly reduced in ASD 
compared with controls. Furthermore, under similar stimulation conditions the presence of 
perforin, granzyme B, and IFNγ in NK cells from ASD children was significantly lower 
compared with controls. Suggestive of possible dysfunction of NK cells, predisposing to the 
development of autoimmunity and/or adverse neuroimmune interactions during critical 
periods of development (Enstrom et al., 2009). 
3.4 Neurokines role in autism spectrum disorders  
Neurokines (neuropoietic cytokines), are neuronal related cytokines, that regulate cell 
numbers in the nervous system and influence functional activities of neurons. They are 
important mediators within the neuroimmune network. These factors are not produced 
exclusively by brain cells and their activities are not restricted to neurons only. Factors with 
neuropoietic activity include CNTF (ciliary neuronotrophic factor), CDF (cholinergic 
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differentiation factor, LIF (leukemia inhibitory factor), Oncostatin M but also IL6, (BDNF, 
NGF, NT-3, NT-4, NT-4, NT-6, GDNF) and factors produced in, or acting upon, the nervous 
system such as bFGF, Interleukins, or TGF-beta.  
There is continual communication between the immune and nervous systems with many 
peptides playing a role in both. It has been proposed frequently that abnormalities in the 
levels and actions of neurotransmitters or neuroactive compounds during early critical 
windows of neurodevelopment may lead to the onset of autism. Neurotransmitters and 
neuropeptides not only have important key roles in the development and organization of 
neural tissue but also influence almost all body functions including the immune system. 
Numerous transmitter systems, including acetylcholine, serotonin (5-HT), dopamine, 
epinephrine, norepinephrine, oxytocin, vasopressin, glutamate, and _-aminobutryic acid 
(GABA), have been studied in ASD (Lam et al., 2006). For example, in postmortem brain 
specimens obtained from patients with ASD, there was a 48– 61% decrease in glutamic acid 
decarboxylase, an enzyme that converts glutamate into GABA, in the parietal and cerebellar 
regions of the brain compared with controls (Fatemi et al., 2002). In ASD, this may cause 
suppression of the GABA-ergic system, resulting in heightened stimulation of the glutamate 
system, which has been associated with seizures. A positive intens autoantibodies reaction  
with GABAergic Golgi neurons of the cerebellum in 21% of children with ASD, were 
demonstrated, while no samples from non-sibling, typically developing children showed 
similar staining reaction (Wills et al., 2009), which in favor of the autoimmunity theory. 
Second, excitotoxic damage of neurons, possibly resulting from glutamate hyperactivity, 
may result in abnormal, structural development of the brain (Bittigau & Ikonomidou, 1997). 
The neurotransmitter serotonin has a wide range of affects on normal physiological 
functions including circadian rhythms, appetite, mood, sleep, anxiety, motor activity, and 
cognition. Serotonin is detected, not only in neurons of the nervous system but also in 
platelets and lymphocytes of the immune system, where it can exert dose-dependent, 
suppressive, or proliferative effects. In normal development, serotonin levels are high in the 
brain up to the age of five and then decrease dramatically (Muzik et al., 1999). Serotonin 
levels increase in the hypothalamus, hippocampus, and cortex in response to various 
cytokines, such as IL-1, IFN (Zhao & Schwartz, 1998; Simmons, & Broderick, 2005). 
Moreover, enzymes that control the conversion of tryptophan into serotonin are under the 
influence of IFN- and IL-1 (Wirleitner et al., 2003). Increased serotonin levels in peripheral 
blood platelets have been described in approximately one-third of patients with autism 
(Anderson et al., 1990). It is interesting that selective serotonin (5-HT) reuptake inhibitors 
(SSRIs) have been shown to be beneficial in treating obsessional and repetitive behaviors in 
some ASD patients sometimes (McDougle et al., 1996). The reason for the difference in 
serotonin levels is unknown; potentially, it may be a result of the presence of inflammatory 
cytokines or more likely, to alterations in the platelets themselves, which could modify 
serotonin uptake (Cook et al., 1996). In spite of the fact that imaging studies demonstrated a 
reduction in brain serotonin system. However, sometimes, treatment with SSRIs, produce a 
worsening of the symptoms. And accordingly, Azmitia et al., (2011), examined 5-HT axons 
that were immunoreactive to a serotonin transporter (5-HTT) antibody in a number of 
postmortem brains from autistic patients and controls with no known diagnosis who ranged 
in age from 2 to 29 years. Results from this study, demonstrated, a fine, highly branched, 
and thick straight fibers were found in forebrain pathways, such as, medial forebrain 
bundle, stria terminalis and ansa lenticularis. Many immunoreactive varicose fine fibers 
were also seen in target areas, for example, globus pallidus, amygdala and temporal cortex. 
www.intechopen.com
 
Autoimmunity in Autism Spectrum Disorders 309 
Morphometric analysis of the stained axons at all ages studied indicated that the number of 
serotonin axons was increased in both pathways and terminal regions in cortex from autism 
donors. Their findings, provide morphological evidence to warrant caution when using 
serotonin enhancing drugs (e.g. SSRIs and receptor agonist) to treat autistic children 
(Azmitia et al., 2011) 
In addition, proinflammatory cytokines IL-1 and TNF are capable of affecting the activity of 
the serotonin transporter gene, a potential susceptibility gene in ASD (Coutinho et al., 2004). 
Cytokines and chemokines play a major role in many stages of development of the CNS and 
are known to induce the secretion of many neurotransmitters and neuropeptides (Biber et 
al., 2002). In turn, neuropeptides play an important role in all phases of immune system 
development, often acting as trophic factors, which has led to the hypothesis that 
neurotrophins (NTs) should be considered as neurokines, as they act in a cytokine like 
manner, influencing the development and function of the immune system (Levi-Montalcini 
et al., 1996). Several NTs with potent immunomodulatory actions, including neuropeptide 
Y, substance P, calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP), 
BDNF, and NT-4/5, which have multiple affects on neurodevelopment and neuron 
maintenance, have been implicated in ASD. Analysis of neonatal blood spots by recycling 
immunoaffinity chromatography found that BDNF, VIP, CGRP, and NT-4/5 were elevated 
in ASD compared with typically developing control children but could not be distinguished 
from those with mental retardation (Nelson et al., 2001). Brain-derived neurotrophic factor is 
a major player in neurodevelopment known to regulate neuronal cell survival, growth, 
plasticity and differentiation, and is now considered to be a growth factor with a wide 
spectrum of functions outside the nervous system, including modulation and regulation of 
immune function (Vega et al., 2003; Nockher & Renz, 2003).  
Based on animal studies, two structurally related neuropeptides, oxytocin and vasopressin, 
are believed to play a critical role in the formation of social bonding and recognition and in 
the processing of social cues (Young et al., 2002). Prairie voles are highly social animals, 
which form long-lasting pair bonds; in contrast, montane voles are asocial or solitary and do 
not form pair bonds (Wang et al., 1998). Central infusion of oxytocin in female or 
vasopressin in male prairie voles helps establish partner-bonding; this phenomenon can be 
blocked using specific antagonists (Williams et al., 1994; Young et al., 2001). Furthermore, 
oxytocin knockout mice have normal, cognitive abilities but diminished social recognition, 
suggesting a key role of oxytocin in social interactions. Other studies (Ferguson et al., 2000; 
Modahl et al., 1998) have found significantly lower levels of plasma oxytocin when 
compared with age-matched, normal subjects. Moreover, this decrease in oxytocin levels 
may be a result of a reduction in the processing of oxytocin, as increased levels of the pro-
hormone form of oxytocin were found in autism patients (AL-Ayadhi 2005c; Green et al., 
2001). In prairie voles, oxytocin and vasopressin receptors are located in the ventral 
forebrain, whereas the pattern of expression of oxytocin receptors differs in montane voles 
(Young et al., 2002). It would seem that not only the concentration of neuropeptides but also 
the pattern of receptor distribution may be important in the establishment of socially 
rewarding interactions. So far, signature patterns of neuropeptides and neurotransmitters 
and their respective receptors have yet to be established in ASD. Further studies that 
address this issue in ASD may provide clues into the development of impaired social 
interactions that are present in ASD. It is interesting that Dunzendorfer et al. (Dunzendorfer 
et al., 2001) have suggested a novel role for neuropeptides in the regulation of dendritic cell 
(DC) migration. They investigated locomotion of mononuclear cell-derived DCs at different 
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maturation stages toward gradients of sensory neuropeptides in vitro. Calcitonin gene-
related peptide, VIP, secretin, and secretoneurin induced immature DC chemotaxis 
comparable with the potency of the chemokine regulated on activation, normal T expressed 
and secreted (RANTES), whereas substance P and macrophage-inflammatory protein-3 
(MIP-3) stimulated immature cell migration only slightly (Dunzendorfer et al., 2001). 
Moreover, the neuropeptide VIP synergized with cytokines such as TNF-in the induction of 
DC maturation (Delneste et al., 1999). In the CNS, DCs have been found in normal 
meninges, the choroid plexus, and CSF and are actively recruited during inflammation, 
where they may play equal roles in the defense against infections and contribute to the 
break-down of tolerance to CNS autoantigens (Pashenkov et al., 2003). These findings 
suggest a central role for DC- and neuropeptide-mediated chemotaxis in the control of CNS 
inflammation and the generation of T cell reactivity against CNS antigens, and present an 
intriguing concept in the context of autism. 
4. Conclusion  
Autism spectrum disorder is a complex, neurodevelopmental, heterogeneous condition, 
with multiple phenotypes and subgroups that share behavioral characters. This natural 
complexity of the disorder has made the pathophysiology and consequently the etiology, 
exceptionally difficult. There is a considerable controversy in the literature regarding an 
immune-based factor in the search for pathophysiological cause in ASD. Nevertheless, with 
increasing reports of immune dysfunction in autism, there is a growing notion and concern 
that immune dysfunction may play a role in a subgroup of patients with ASD. Attempts 
have been made to link dysfunctional immune activity and ASD, such as maternal immune 
abnormalities during early pregnancy, increased incidence of familial autoimmunity, 
childhood vaccinations, and the generation of autism animal models based on immune 
parameters. Starting from the embryonic stage of life, to postnatal, and to adult hood, both 
neurological and immune systems are intertwined and abnormalities in one of them will be 
reflected on the other with dysregulation altering levels of cytokines, chemokines, 
neurotransmitters, neuropeptides, as well as hormones. Each of these substances may 
influence the course of development in the nervous and/or immune systems primarily or 
through secondary action. Moreover, while the extent to which many of the observations 
discussed herein are involved in the pathogenesis of autism is unknown, it cannot be 
discounted that immune dysfunction is an epiphenomenon or a consequence of the disease. 
Comprehensive extensive studies of autism and age-matched control individuals and their 
families are mandatory for more conclusive results.  
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